Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
The malignant lymphomas, Hodgkin´s disease (HD) and non-Hodgkin´s lymphoma (NHL), comprise approximately 5-6% of all malignancies in adults and account for 10% of childhood cancers. Once the diagnosis has been established histologically, extent of disease (staging) and response to therapy will be assessed by means of a computed tomography (CT) scan of the body. The staging at presentation is important for determining prognosis and choice of treatment. Unfortunately, CT is accompanied by a significant amount of radiation exposure which may induce second cancers. This is especially important in childhood, because rapidly dividing cells are more sensitive to radiation induced effects and children will have more years ahead in which cancerous changes might occur. New magnetic resonance imaging (MRI) techniques offer an alternative way for staging and follow-up of cancers, including the malignant lymphomas. Whole-body MRI (WB-MRI) is a radiation-free method which allows imaging of the body with excellent soft tissue contrast in a single examination.
The aim of this study is to examine if WB-MRI can replace CT in staging of patients with a malignant lymphoma.
This will be a multicenter, prospective, diagnostic cohort study (timeschedule: 36 months). 135 eligible patients will undergo WB-MRI on top of the protocolar imaging routinely done.
Patients aged 8 years and older with a histological diagnosis of HD or NHL.
The challenge of this study will be to show non-inferiority of WB-MRI compared to CT in staging malignant lymphoma. Testing of this hypothesis will be one-sided and performed using recently proposed techniques by Lui et al.
Radiation-related risk assessment:
A risk model will be used, based on the BEIR VII report, for modelling the late-term mortality from radiation induced tumors after exposure to ionizing radiation.
Actual costs (from a societal perspective) will be determined for the two diagnostic tests. In case of clinical equivalence and similar costs or cost savings associated with MRI the latter can be considered dominant, obviating further economic evaluation. Otherwise, through modelling of expected long term health impact and associated outcomes such as quality of life and costs the incremental cost effectiveness will be evaluated.
|Malignant Lymphoma Hodgkin's Disease Non-Hodgkin's Lymphoma|
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Whole-body MR Imaging for Staging Malignant Lymphomas|
- The primary outcome will be the clinical stage according to WB-MRI findings and according to CT-findings. This clinical stage will be determined according to the Ann Arbor classification system. [ Time Frame: December 2010 ]
- The secondary outcome will be a (subjective) assessment of image quality and presence of artefacts, for both T1-weighted and T2-weighted MR images as well as CT. [ Time Frame: December 2010 ]
|Study Start Date:||June 2008|
|Study Completion Date:||June 2012|
|Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00685997
|Academic Medical Center Amsterdam|
|Amsterdam, Noord-Holland, Netherlands, 1105 AZ|
|Meander Medical Center Amersfoort|
|Amersfoort, Utrecht, Netherlands, 3818 ES|
|University Medical Center Utrecht|
|Utrecht, Netherlands, 3584 CX|
|Principal Investigator:||Rutger A. J. Nievelstein, MD PhD||UMC Utrecht|